trial · primary record
Obrixtamig
Small Cell Lung Carcinoma (SCLC)
| Phase | Phase 1 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 45 |
| Primary completion | 2027-03-31 |
| Primary endpoint | Occurrence of Dose Limiting Toxicities (DLTs) in the Maximum Tolerated Dose (MTD) evaluation period |
| Registry ID | NCT05879978 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:45.620Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05879978
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.